Healthcare Triangle Announces Reverse Stock Split to Maintain Nasdaq Listing

Healthcare Triangle, Inc. (Nasdaq: HCTI) has announced a 1-for-249 reverse stock split of its common stock, effective from 12:01 a.m. Eastern Time on August 1, 2025. This strategic decision is designed to elevate the company's share price to meet the Nasdaq Capital Market's $1.00 minimum bid price requirement, ensuring compliance and continued trading under the symbol 'HCTI'. The move is crucial for maintaining the company's listing on a major U.S. stock exchange, which is vital for liquidity, institutional investment, and overall market credibility. Failure to meet such listing standards can lead to delisting, severely restricting trading access and diminishing investor trust.

The reverse stock split, which received stockholder approval during a special meeting on February 26, 2025, will convert every 249 shares of the company's outstanding common stock into one share. This adjustment is expected to reduce the number of outstanding shares from approximately 1,452,124,283 to about 5,831,850, without altering the par value or the total number of authorized shares. Fractional shares will not be issued; instead, stockholders will receive a rounded-up share at the participant level. Such a consolidation directly impacts the share structure, making the stock appear more valuable on a per-share basis, which can influence market perception and potentially attract a broader investor base that often avoids low-priced stocks due to perceived risk or volatility.

Stockholders of record as of August 1, 2025, will be informed about their updated share ownership by the company's transfer agent, VStock Transfer, LLC. Further details regarding the reverse stock split are available in the company's definitive information statement on Schedule 14C, filed with the U.S. Securities and Exchange Commission on March 17, 2025, and accessible at https://sec.gov. This filing provides transparency and legal documentation for the corporate action, allowing investors to review the specifics. The importance of this announcement extends beyond mere compliance; it reflects a proactive measure to stabilize the company's market position. For a provider of digital transformation solutions in healthcare and life sciences, maintaining a Nasdaq listing supports ongoing operations, partnerships, and growth initiatives by preserving access to public capital markets. The implications are significant for shareholder value, as continued listing helps prevent the negative stigma and operational hurdles associated with delisting, thereby safeguarding the company's strategic trajectory in a competitive sector.